Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
Rheumatic Heart Disease IV: Nursing Management01:20

Rheumatic Heart Disease IV: Nursing Management

AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Quality in acute inpatient rheumatology 2021 : Current aspects of the KOBRA quality label of the Association of Rheumatological Acute Care Clinics].

Zeitschrift fur Rheumatologie·2021
Same author

[Outpatient specialist medical treatment (ASV)-a new treatment level in rheumatology].

Zeitschrift fur Rheumatologie·2019
Same author

[Standards of care for people with rheumatoid arthritis in Europe : Translation and comments of the eumusc.net recommendations supported by EULAR performed by a national task force of the professional organisations DGRh and VRA supported by "Deutsche Rheumaliga"].

Zeitschrift fur Rheumatologie·2016
Same author

[International quality indicators in rheumatology. Suggestions for rheumatoid arthritis].

Zeitschrift fur Rheumatologie·2016
Same author

[Hospital financing in 2016. Relevant changes for rheumatology].

Zeitschrift fur Rheumatologie·2016
Same author

[Hospital financing in 2015. Relevant changes for rheumatology].

Zeitschrift fur Rheumatologie·2015
Same journal

[Prevention strategies in rheumatoid arthritis : From primary prevention to targeted drug interception].

Zeitschrift fur Rheumatologie·2026
Same journal

Methodological concerns and data discrepancies in the indirect treatment comparison of belimumab and anifrolumab.

Zeitschrift fur Rheumatologie·2026
Same journal

Evaluating the comparative efficacy of belimumab vs. anifrolumab in systemic lupus erythematosus: a response.

Zeitschrift fur Rheumatologie·2026
Same journal

[Update: DMARDs for MGUS].

Zeitschrift fur Rheumatologie·2026
Same journal

[A potpourri of diagnoses-Unusual manifestations of a chronic inflammatory bowel disease : Case report].

Zeitschrift fur Rheumatologie·2026
Same journal

[Not measurable but immeasurably important : Fever-The leading symptom of ancient medical theory].

Zeitschrift fur Rheumatologie·2026
See all related articles

Related Experiment Video

Updated: Jun 21, 2026

Automated Joint Space Detection Improves Bone Segmentation Accuracy
06:45

Automated Joint Space Detection Improves Bone Segmentation Accuracy

Published on: November 28, 2025

[G-DRG system 2009: relevant changes for rheumatology].

W Fiori1, A Liedtke-Dyong, H-J Lakomek

  • 1DGR-Research-Group, Medizinisches Management, Universitätsklinikum Münster, 48129 Münster. wolfgang.fiori@ukmuenster.de

Zeitschrift Fur Rheumatologie
|July 18, 2009
PubMed
Summary
This summary is machine-generated.

The 2009 German diagnosis-related groups (G-DRG) system introduces national weighting for complex rheumatologic treatment (I97Z) and emphasizes case auditing. Hospitals must analyze economic impacts on their rheumatology departments.

Related Experiment Videos

Last Updated: Jun 21, 2026

Automated Joint Space Detection Improves Bone Segmentation Accuracy
06:45

Automated Joint Space Detection Improves Bone Segmentation Accuracy

Published on: November 28, 2025

Area of Science:

  • Health economics
  • Medical classification systems
  • Hospital administration

Context:

  • The German diagnosis-related groups (G-DRG) system underwent significant changes in 2009.
  • These changes affected diagnosis and procedure classification, and the billing process.
  • National weighting for complex rheumatologic treatment (G-DRG I97Z) was a key development.

Purpose:

  • To detail the general and specific modifications within the 2009 G-DRG system.
  • To highlight the introduction of national weighting for G-DRG I97Z, previously negotiated individually.
  • To emphasize the role of case auditing by health insurers and the need for economic analysis by hospitals.

Summary:

  • The 2009 G-DRG system update includes changes to classification and billing.
  • National weighting for G-DRG I97Z (complex rheumatologic treatment) is now established.
  • Hospitals must evaluate the economic consequences using the G-DRG transition grouper, considering potential impacts on rheumatology departments.

Impact:

  • Hospitals need to assess the economic effects of the 2009 G-DRG system on their specific cases.
  • Rheumatological departments may face varied financial outcomes based on their clinical focus.
  • The study separates the impact of G-DRG redistribution from the broader issue of inadequate hospital cost refunding.